The mAbs were administered via the tail vein under anesthesia, and the injection volume was 0.4 mL.
Multiple cycles of labelled mAbs were administered (mean, three per patient) at various activity levels.
Once mAbs are administered into the bloodstream, they can distribute into cancer tissue either via extravasation through pores in the endothelium or via pinocytosis through endothelial cells following a diffusion gradient [ 89].
Furthermore, as summarized in the five included article in this study [35 39], CGRP-mAbs were administered subcutaneously or intravenously, allowing for monthly or even quarterly dosing due to their long half-lives and absence of liver toxicity.
In particular, 95% of mice were protected when 500 μg of mAb were administered intraperitoneally and concomitantly to intramuscular injection of JEV.
In particular, they found that the singularly mAb protection ranged from 45 to 65% when 100 μg of mAb were administered, while equimolar combinations of two or three mAbs gave 85 90% or 100% protection, respectively [ 113].
Nine-week-old male C57BL/6 mice were inoculated with H1N1, then anti-HMGB1 mAb or control mAb were administered intravenously at 1, 24 and 48 hours after H1N1 inoculation and the survival rate was analyzed.
Anti-IL-12p40 mAb was administered i.p. on D0, D3 or both days post CPS vaccination.
For blocking experiments, 1 mg of unmodified anti-CA125 MAb was administered intraperitoneally 24 h prior to injection of the 64Cu-labeled radioimmunoconjugates.
In humans undergoing trastuzumab therapy, the mAb is administered at concentrations >5 mg/kg.[59] Based on the human values, a therapeutic dose of trastuzumab in a typical 20 25 g mouse, corresponds to 100 125 µg of mAb.
